Preparation of doxorubicin-containing B7-H3 immune long-circulating liposomes and its inhibitory effect on viabilities of MCF-7 cells
Objective Doxorubicin(DOX)was used as the model drug and B7-H3 immune liposome was used as the carrier to construct the DOX-carrying immune long-circulating liposome(B7-H3-PEG-DOX-Lips,BPDL),and the phar-macokinetic behavior of BPDL in SD rats and its toxic effect on human breast cancer MCF-7 cells were evaluated.Methods The DOX-containing liposome BPDL was prepared by thin film dispersion method.The microscopic morphology of BPDL was observed by transmission electron microscope.The particle size distribution and zeta potential were determined by laser particle size analyzer.The in vitro drug release was investigated by dialysis,and the in vivo pharmacokinetics were evaluated using SD rats as models to compare the toxic effects of DOX,DOX-Lips and BPDL on human breast cancer MCF-7 cells in vitro.Results The average particle size of BPDL was 152.27 nm,the potential was-25.9 mV,and the DOX loading was 8.16％±0.08％.When BPDL was released in phosphate buffer solution for 96 h,the cumulative release rate of DOX was 60.15％.Compared with the bulk drug,MRT,Cmax and CLz of BPDL liposomes were increased,and the t1/2 of DOX was 3.59 times longer than that of free drug group(P＜0.05).In the cytotoxicity experiment,when the concentration of DOX in BPDL was 160 μg·mL-1,the inhibition rate of MCF-7 reached 97.48％under the condition of 72 h of administration.Conclusion The long-circulating liposome conjugated with B7-H3 antibody prepared in this study can prolong the circulation time of drugs in the blood,and has a strong inhibitory effect on human breast cancer cells,providing a new scientific research idea for the development of chemotherapy combined with immunotherapy.
B7-H3AdriamycinImmune liposomesPharmacokineticsCytotoxicityBreast cancer
国家科技期刊平台
NSTL
万方数据
